Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
ACS Medicinal Chemistry Letters|November 20, 2024
Invention of VH-937, a Potent HIV-1 Maturation Inhibitor with the Potential for Infrequent Oral Dosing in HumansSing-Yuen Sit, Yan Chen, Jie Chen, et al.ACS Medicinal Chemistry Letters|February 20, 2018
Potent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond DonorBarbara Zheng, Stanley V D'Andrea, Li-Qiang Sun, et al.ACS Medicinal Chemistry Letters|June 16, 2022
Discovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase InhibitorKyle Parcella, Tao Wang, Kyle Eastman, et al.Journal of Medicinal Chemistry|November 23, 2020
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus InfectionLi-Qiang Sun, Eric Mull, Stanley D'Andrea, et al.Journal of Medicinal Chemistry|February 22, 2014
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infectionPaul M Scola, Alan Xiangdong Wang, Andrew C Good, et al.Journal of Medicinal Chemistry|February 26, 2014
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infectionPaul M Scola, Li-Qiang Sun, Alan Xiangdong Wang, et al.Journal of Medicinal Chemistry|August 27, 2016
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily DosingLi-Qiang Sun, Eric Mull, Barbara Zheng, et al.Pageof 2